Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHEDREA morphine clearance and glomerular filtration in sickle cell crisis in ICU
2024-511985-34-00Phase 4Authorised
- Sponsor
- CHRU Tours
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of morphine in sickle cell disease (SCD), vaso-occlusive crisis (VOC) and acute chest syndrome (ACS), sponsored by CHRU Tours. Planned start Jul 2025; status: authorised.
02
Drugs
morphine
03
Conditions
sickle cell disease (SCD)vaso-occlusive crisis (VOC)acute chest syndrome (ACS)
Beyond the preview
Go deeper on 2024-511985-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511985-34-00.